罗氏开发新一代DNA测序技术——纳米微孔测序技术

浏览次数：5773　发布日期：2011-10-19　来源：本站　本站原创，转载请注明出处

罗氏联合亚利桑那州立大学、哥伦比亚大学以及IBM研发新一代DNA测序技术

罗氏于10月11日宣布已与亚利桑那科技公司（Arizona Technology Enterprises，AzTE）签订协议，获得由亚利桑那州州立大学 Biodesign研究所Dr. Stuart Lindsay以及哥伦比亚大学纳米科学研究中心 Dr. Colin Nuckolls 开发的数项DNA测序新技术的许可证，这些技术包括DNA碱基探测及读出方法。至此，罗氏454测序中心将联合两家实验室以及IBM研发新一代单分子基于纳米微孔技术的DNA测序仪，该技术有望将个人基因组测序成本降到1000美金以下。

这项新技术可以读出正在通过纳米微孔的DNA分子的单个或者几个碱基，并且已经获得了实验证实。目前正在研发第三代DNA碱基解读分子，以获得更好的碱基序列读出。这次签订的协议将推动这些新技术的产业化。

Dr. Stuart Lindsay是亚利桑那州州立大学 Biodesign研究所单分子生物研究主任，介绍说：“我们的新技术结合了先进的物理、电子、纳米科技，将改变DNA测序的基本设计概念，在整个测序过程中不使用化学试剂，将消除测序的试剂成本。”

罗氏454 Life Sciences公司总裁 Thomas Schinecker先生说：“Biodesign研究所的这个项技术是目前正在发展的纳米微孔测序系统中最好的技术之一，对这个领域的发展起着非常重要的作用。我们早前已经宣布了与IBM公司合作，开发DNA晶体管技术，而两者可以很好地结合进一步开发出新一代超级快速、低成本的DNA测序仪。”

由IBM公司研发的DNA晶体管技术，可以控制DNA分子缓慢通过硅晶芯片的纳米微孔，而新获得这项技术可以当DNA分子在通过纳米微孔时解码其碱基序列。两项技术都基于半导体为基质的纳米微孔，比起依赖于蛋白质分子的纳米微孔技术更加容易控制、更高产率、更易提高通量及用于工业生产。

这次的协议是通过亚利桑那科技公司签订的，它是亚利桑那州立大学指定的知识产权管理机构，协议同时包括了以帮助Lindsay的研究小组将其成果产业化的一项基金。Lindsay及其同事Bharath Takulapalli最近还获得了美国国家人类基因组研究中心（NHGRI）颁发的超过500万美金的奖金以表彰他们在测序领域的工作。

Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing

Oct 11, 2011 - fuchsc8

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Arizona Technology Enterprises (AzTE) announced today an agreement to license several technologies developed by Dr. Stuart Lindsay at the Biodesign Institute at Arizona State University and Dr. Colin Nuckolls of the Columbia University Nanoscience Center for the development of a revolutionary DNA sequencing system. The licensed technologies include specialized approaches for DNA base sensing and reading and build on an ongoing collaboration between Roche’s sequencing center of excellence, 454 Life Sciences, and IBM (NYSE: IBM) to develop and commercialize a single-molecule, nanopore DNA sequencer with the capacity to rapidly decode an individual’s complete genome for well below $1000.

The licensed technologies offer novel approaches for reading the sequence of bases, or letters, in a single DNA molecule as it is passed through a nanopore. The team has demonstrated proof-of-concept, and is in the midst of making a third generation reader molecule that provides better discrimination between the DNA bases. The licensing agreement with Roche will help translate these discoveries into a commercial instrument.

“Our promising approach, which combines advances in physics, electronics and nanotechnology, eliminates the need for the use of a major cost of sequencing today – namely, the use of chemical reagents – to read an individual’s genome,” said Lindsay, an ASU Regents’ Professor and Director of the Biodesign Institute’s Center for Single Molecule Biophysics.

“We believe that the DNA reading technologies from the Biodesign Institute are the most advanced available, and will play an important role in our nanopore sequencing system currently under development,” says Thomas Schinecker, President of 454 Life Sciences, a Roche Company, “This will complement the DNA Transistor technology from our previously announced collaboration with IBM very well to form the core of a superior platform for extremely fast, very low-cost genome sequencing.”

The DNA Transistor technology, developed by IBM Research, slows and controls the movement of the DNA molecule as it threads through a microscopic nanopore in a silicon chip, while the newly licensed DNA reading technology can decode the bases of the DNA molecule as it passes through. Both technologies are centered on semiconductor-based nanopores, which have advantages over protein-based nanopores in terms of control, robustness, scalability, and manufacturability.

The deal was brokered by Arizona Technology Enterprises (AzTE), the exclusive intellectual property management and technology transfer organization of Arizona State University, and includes sponsored research funding that will help Lindsay’s team move the technology towards commercialization. The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), recently awarded Lindsay and fellow Biodesign researcher Bharath Takulapalli more than $5 million for their work in DNA sequencing. ASU was the only university to receive more than one award.

About Columbia Technology Ventures

A leading academic and research university, Columbia University continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Columbia University's technology transfer office, Columbia Technology Ventures, manages Columbia’s intellectual property portfolio and serves as the university’s gateway for companies and entrepreneurs seeking novel technology solutions. Our core mission is to facilitate the transfer of inventions from academic research to outside organizations for the benefit of society on a local, national and global basis. For more information on Columbia Technology Ventures, please visit www.techventures.columbia.edu

【点击可查看罗氏诊断产品（上海）有限公司相关产品】

分享到：QQ空间新浪微博腾讯微博微信

【所有新闻】【本类新闻】【相关产品】【关闭窗口】